Image Ben Hargreaves R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics. Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies. Oncology Words matter: The power of language in cancer discussions The priority for any individual diagnosed with cancer is to be provided an effective therapy as quickly as possible. Oncology Why is pharma going gaga for radiopharmaceuticals? The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage. Load more results
R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.
Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
Oncology Words matter: The power of language in cancer discussions The priority for any individual diagnosed with cancer is to be provided an effective therapy as quickly as possible.
Oncology Why is pharma going gaga for radiopharmaceuticals? The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.